Related Experiment Video
Updated: Aug 1, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
LY146032: activity and resistance development in vitro
1Department of Medical Microbiology, University Hospital Leiden, The Netherlands.
Abstract:
LY146032, a new lipopeptide antibiotic, was compared with vancomycin, teicoplanin, cefamandole and ciprofloxacin, against 107 clinical isolates comprising methicillin-susceptible and methicillin-resistant Staphylococcus spp., Streptococcus faecalis and Corynebacterium spp. All staphylococci were susceptible to all agents, except that some of the methicillin-resistant strains were resistant to cefamandole. Only LY146032 and ciprofloxacin were bactericidal to Str. faecalis. Development of resistance was studied by serial transfers of ten selected strains. A stable greater than or equal to eight-fold increase of the MIC over the breakpoint was found to develop to a variable extent against all agents tested. Simultaneous development of resistance to any of the other antibiotics was registered in 11/200 tests.
Insights
LY146032, a novel lipopeptide antibiotic, demonstrated broad-spectrum activity against Gram-positive bacteria, including resistant strains. While resistance developed to all tested antibiotics, LY146032 showed promising bactericidal effects against specific pathogens.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antibiotic resistance is a growing global health threat, necessitating the development of new antimicrobial agents.
- Gram-positive bacteria, including Staphylococcus spp. and Streptococcus faecalis, are significant causes of hospital-acquired infections.
- Existing antibiotics like vancomycin and teicoplanin face challenges with emerging resistance.
Purpose of the Study:
- To evaluate the in vitro activity of LY146032, a novel lipopeptide antibiotic, against a panel of clinical isolates.
- To compare the efficacy of LY146032 with established antibiotics: vancomycin, teicoplanin, cefamandole, and ciprofloxacin.
- To assess the potential for resistance development to LY146032 and other agents.
Main Methods:
- Antimicrobial susceptibility testing was performed on 107 clinical isolates, including methicillin-susceptible and methicillin-resistant Staphylococcus spp., Streptococcus faecalis, and Corynebacterium spp.
- Bactericidal activity was assessed for LY146032 and ciprofloxacin against Streptococcus faecalis.
- Resistance development was studied through serial transfer experiments with ten selected strains to determine minimum inhibitory concentration (MIC) changes.
Main Results:
- All tested staphylococci were susceptible to LY146032, vancomycin, teicoplanin, and ciprofloxacin. Some methicillin-resistant strains showed resistance to cefamandole.
- LY146032 and ciprofloxacin exhibited bactericidal activity against Streptococcus faecalis.
- A stable, greater than or equal to eight-fold increase in MIC was observed against all tested agents, indicating variable resistance development. Simultaneous resistance to other antibiotics occurred in 11/200 tests.
Conclusions:
- LY146032 demonstrates potent in vitro activity against a range of Gram-positive bacteria, including resistant strains.
- The lipopeptide antibiotic shows bactericidal potential against Streptococcus faecalis.
- While resistance can develop to LY146032, its profile warrants further investigation as a potential therapeutic agent.
More Related Videos
10:51Fabrication and Validation of an Organ-on-chip System with Integrated Electrodes to Directly Quantify Transendothelial Electrical Resistance
Published on: September 26, 2017
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022